GSK's Health Management Innovations team is also analyzing the results
of several other studies investigating potential factors affecting patient
compliance, including assessing the impact of:
-- copayment level on specific outcomes such as Hba1c levels for diabetic
-- income on initial copayment levels and increases in copayment levels
-- implementing a consumer-directed health plan
-- implementing a pay-for-performance initiative
Formal results of these studies will be announced as they are published.
To hear more about this study, visit http://www.med.umich.edu/opm/newspage/2008/drugcopay.asx.
GlaxoSmithKline, one of the world's leading research-based pharmaceutical and health care companies, is committed to improving the quality of human life by enabling people to do more, feel better, and live longer.
1. Haynes RB, Yao X, Degani A et al. Interventions to enhance medication adherence. Cochrane Database Syst Rev. 2005:CD000011.
2. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002;288:2868-2879.
3. Kaiser Family Foundation and Health Research and Educational Trust. Annual Surveys of Employer-Sponsored Health Benefits, 2000-2005.
4. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11:730-740.
5. Lexchin J, Grootendorst P. Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence. Int J Health Serv. 2004;34:101-122.
6. Goldman DP, Joyce GF, Escarce JJ et al. Pharmacy benefits and the
use of drugs by the chronically
Copyright©2008 PR Newswire.
All rights reserved